JP2023531522A5 - - Google Patents
Info
- Publication number
- JP2023531522A5 JP2023531522A5 JP2022579740A JP2022579740A JP2023531522A5 JP 2023531522 A5 JP2023531522 A5 JP 2023531522A5 JP 2022579740 A JP2022579740 A JP 2022579740A JP 2022579740 A JP2022579740 A JP 2022579740A JP 2023531522 A5 JP2023531522 A5 JP 2023531522A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- agents
- composition
- cancer cells
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044926P | 2020-06-26 | 2020-06-26 | |
| US63/044,926 | 2020-06-26 | ||
| PCT/US2021/039248 WO2021263205A1 (en) | 2020-06-26 | 2021-06-25 | Combination therapy with deoxyuridine triphosphatase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531522A JP2023531522A (ja) | 2023-07-24 |
| JP2023531522A5 true JP2023531522A5 (https=) | 2024-06-13 |
Family
ID=77520789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579740A Pending JP2023531522A (ja) | 2020-06-26 | 2021-06-25 | デオキシウリジントリホスファターゼ阻害剤との併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230263773A1 (https=) |
| EP (1) | EP4171549B1 (https=) |
| JP (1) | JP2023531522A (https=) |
| CN (1) | CN115843249A (https=) |
| AU (1) | AU2021297566A1 (https=) |
| BR (1) | BR112022026247A2 (https=) |
| CA (1) | CA3185648A1 (https=) |
| IL (1) | IL298855A (https=) |
| WO (1) | WO2021263205A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116271008A (zh) * | 2022-12-30 | 2023-06-23 | 广东天普生化医药股份有限公司 | 含有安柯瑞和卡瑞利珠单抗的药物组合物及其应用 |
| GB202308160D0 (en) * | 2023-05-31 | 2023-07-12 | Lario Therapeutics Ltd | Compounds |
| GB202308164D0 (en) * | 2023-05-31 | 2023-07-12 | Lario Therapeutics Ltd | Compounds |
| GB202308165D0 (en) * | 2023-05-31 | 2023-07-12 | Lario Therapeutics Ltd | Compounds |
| CN116769722B (zh) * | 2023-07-04 | 2024-07-16 | 杭州荣谷生物科技有限公司 | 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962246A (en) | 1996-03-29 | 1999-10-05 | The University Of Medicine And Dentistry Of New Jersey | dUTPase, its isoforms, and diagnostic and other uses |
| US8530490B2 (en) | 2008-06-03 | 2013-09-10 | Taiho Pharmaceutical Co., Ltd. | Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity |
| US20110212467A1 (en) | 2008-08-27 | 2011-09-01 | University Of Southern California | INHIBITORS OF dUTPase |
| CN103948599B (zh) | 2009-11-30 | 2016-03-09 | 大鹏药品工业株式会社 | 抗肿瘤效果增强剂 |
| CA2914178C (en) | 2013-01-07 | 2023-06-13 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| PT3319939T (pt) * | 2015-07-08 | 2025-03-05 | Cv6 Therapeutics Ni Ltd | Inibidores de desoxiuridina-trifosfatase contendo hidantoína |
| WO2017119484A1 (ja) * | 2016-01-08 | 2017-07-13 | 大鵬薬品工業株式会社 | 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |
| US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US10829457B2 (en) | 2016-11-23 | 2020-11-10 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| US11168059B2 (en) | 2016-11-23 | 2021-11-09 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
-
2021
- 2021-06-25 AU AU2021297566A patent/AU2021297566A1/en active Pending
- 2021-06-25 CA CA3185648A patent/CA3185648A1/en active Pending
- 2021-06-25 IL IL298855A patent/IL298855A/en unknown
- 2021-06-25 WO PCT/US2021/039248 patent/WO2021263205A1/en not_active Ceased
- 2021-06-25 EP EP21762534.2A patent/EP4171549B1/en active Active
- 2021-06-25 CN CN202180044470.6A patent/CN115843249A/zh active Pending
- 2021-06-25 BR BR112022026247A patent/BR112022026247A2/pt unknown
- 2021-06-25 JP JP2022579740A patent/JP2023531522A/ja active Pending
- 2021-06-25 US US18/010,774 patent/US20230263773A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531522A5 (https=) | ||
| CN107405401B (zh) | 用于治疗癌症的pd-1/pd-l1抑制剂 | |
| JP2023530128A (ja) | 細胞結合分子とカンプトテシン類縁体との共役体 | |
| JP2021527431A5 (https=) | ||
| JP2024028815A (ja) | チューブリシン類縁体と細胞結合分子との共役体の製剤 | |
| JP2020517640A5 (https=) | ||
| JP7830412B2 (ja) | １，２，４－オキサジアゾール化合物を用いてｔｉｇｉｔおよびｐｄ－１のシグナル伝達経路をモジュレートする方法 | |
| AU2015243379A1 (en) | Tubulysin derivatives | |
| JP7402691B2 (ja) | 抗ｃｄ２５抗体薬物複合体による併用療法 | |
| JP2017515802A5 (https=) | ||
| RS54525B1 (sr) | Sredstva i postupci za tretiranje dlbcl | |
| JP2021533124A (ja) | Ｉａｐ阻害剤及び免疫チェックポイント分子の調節剤の組合せによる癌を治療するための方法 | |
| KR20210095868A (ko) | 면역 체크포인트 저해약 및 폴피리녹스 요법과의 병용에 의한 암 치료 | |
| TW202114740A (zh) | 一種細胞結合分子-tubulysin衍生物偶聯物及其製備方法 | |
| EP3755371A1 (en) | Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen | |
| CN113286614A (zh) | 用于治疗癌症的pd-1拮抗剂、atr抑制剂和铂化物质的组合 | |
| WO2020111234A1 (ja) | 組み合わせ医薬として用いられるｅｚｈ１／２二重阻害剤を含有する医薬組成物 | |
| JP2024536383A5 (https=) | ||
| EP3897844B1 (en) | Pharmaceutical combination of anti ceacam6 and tim3 antibodies | |
| JP2023502023A (ja) | Ｃｄ２００受容体アンタゴニスト結合分子 | |
| EP3880705A1 (en) | Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer | |
| Kiełbowski et al. | Immunotherapeutics and other anticancer agents in the management of advanced gastric cancer | |
| KR20260062972A (ko) | 3,5-2치환 벤젠알키닐 화합물과 면역 체크 포인트 저해약을 포함하는 암치료법 | |
| TW202517295A (zh) | 包含3,5-二取代苯炔基化合物與免疫檢查點抑制藥之癌症治療法 | |
| HK40040793A (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer |